Optimal Medication Dosing in Patients with Diabetes Mellitus and Chronic Kidney Disease

被引:13
作者
MacCallum, Lori [1 ]
机构
[1] Univ Toronto, Leslie Dan Fac Pharm, Sun Life Financial Prof Wellness & Diabet Educ, Banting & Best Diabet Ctr,Fac Med & Assistant Pro, Toronto, ON, Canada
关键词
chronic kidney disease; diabetes; medication dosing; renal impairment; COCKCROFT-GAULT EQUATIONS; GLOMERULAR-FILTRATION-RATE; RENAL-DISEASE; SERUM CREATININE; DIET; PHARMACOKINETICS; IMPAIRMENT; HYPOGLYCEMIA; SAXAGLIPTIN; REPAGLINIDE;
D O I
10.1016/j.jcjd.2014.04.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus is the leading cause of chronic kidney disease (CKD) in Canada. As rates of diabetes rise, so does the prevalence of CKD. Diabetes and CKD are chronic diseases that require multiple medications for their management. Many of the anticipated effects of these medications are altered by the physiologic changes that occur in CKD. Failure to individualize drug dosing in this population may lead to toxicity or decreased therapeutic response, leading to treatment failure. At times this can be challenging for a multitude of reasons, including the limitations of available calculations for estimating renal function, inconsistent dosing recommendations and the lack of dosing recommendations for some medications. Clinicians caring for these patients need to consider an approach of individualized drug therapy that will ensure optimal outcomes. The better understanding that clinicians have of these challenges, the more effective they will be at using the available information as a guide together with their own professional judgement to make appropriate dosing changes. This article discusses the following: 1) physiologic changes that occur in CKD and its impact on drug dosing; 2) advantages and disadvantages of various calculations used for estimating renal function; 3) pharmacokinetic and pharmacodynamic changes of some commonly used medications in diabetes, and finally, 4) an approach to individualized drug dosing for this patient population. (C) 2014 Canadian Diabetes Association
引用
收藏
页码:334 / 343
页数:10
相关论文
共 59 条
  • [1] [Anonymous], NOT GUID EV PHARM ME
  • [2] [Anonymous], NEW ENGL J MED
  • [3] [Anonymous], GLYBURIDE MONOGRAPH
  • [4] [Anonymous], COCHRANE DATABASE SY
  • [5] [Anonymous], 2010, GUID IND PHARM PAT I
  • [6] [Anonymous], BR J CLIN PHARM
  • [7] [Anonymous], 1998, PHARM PAT IMP REN FU
  • [8] [Anonymous], LINAGLIPTIN MONOGRAP
  • [9] [Anonymous], ANN REP TREATM END S
  • [10] [Anonymous], PHARMACOTHERAPY PATH